The efficacy and safety of the anti–PD-L1 immunotherapy atezolizumab in patients with previously treated advanced or metastatic NSCLC was investigated initially in a phase 2 POPLAR clinical trial, and later in a phase 3 OAK trial [10]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.